Terms: = Prostate cancer AND CCND1, BCL1, 595, ENSG00000110092, PRAD1, U21B31, D11S287E AND Treatment
68 results:
1. The Molecular, Immunologic, and Clinicodemographic Landscape of MYC-Amplified Advanced prostate cancer.
Jin WH; Zhang L; Graf R; Raskina K; Tukachinsky H; Huang RSP; McGregor K; Alshalalfa M; Hougen HY; Khan A; Punnen S; Schrock AB; Venstrom J; Mahal BA
Clin Genitourin Cancer; 2024 Feb; 22(1):e163-e169.e1. PubMed ID: 37978032
[TBL] [Abstract] [Full Text] [Related]
2. Genomic characterization of IDH-mutant astrocytoma progression to grade 4 in the treatment setting.
Rautajoki KJ; Jaatinen S; Hartewig A; Tiihonen AM; Annala M; Salonen I; Valkonen M; Simola V; Vuorinen EM; Kivinen A; Rauhala MJ; Nurminen R; Maass KK; Lahtela SL; Jukkola A; Yli-Harja O; Helén P; Pajtler KW; Ruusuvuori P; Haapasalo J; Zhang W; Haapasalo H; Nykter M
Acta Neuropathol Commun; 2023 Nov; 11(1):176. PubMed ID: 37932833
[TBL] [Abstract] [Full Text] [Related]
3. Development and validation of a nomogram to predict cancer-specific survival in nonsurgically treated elderly patients with prostate cancer.
Zhang Z; Cai Q; Wang J; Yao Z; Ji F; Hang Y; Ma J; Jiang H; Yan B; Zhanghuang C
Sci Rep; 2023 Oct; 13(1):17719. PubMed ID: 37853026
[TBL] [Abstract] [Full Text] [Related]
4. Metastatic prostate cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical Outcomes.
Hwang J; Shi X; Elliott A; Arnoff TE; McGrath J; Xiu J; Walker P; Bergom HE; Day A; Ahmed S; Tape S; Makovec A; Ali A; Shaker RM; Toye E; Passow R; Lozada JR; Wang J; Lou E; Mouw KW; Carneiro BA; Heath EI; McKay RR; Korn WM; Nabhan C; Ryan CJ; Antonarakis ES
Clin Cancer Res; 2023 Jul; 29(14):2702-2713. PubMed ID: 37126020
[TBL] [Abstract] [Full Text] [Related]
5. EffectiveNess of a multimodal preHAbilitation program in patieNts with bladder cancer undergoing radical cystectomy: protocol of the ENHANCE multicentre randomised controlled trial.
Akdemir E; Sweegers MG; Vrieling A; Rundqvist H; Meijer RP; Leliveld-Kors AM; van der Heijden AG; Rutten VC; Koldewijn EL; Bos SD; Wijburg CJ; Marcelissen TAT; Bongers BC; Retèl VP; van Harten WH; May AM; Groen WG; Stuiver MM
BMJ Open; 2023 Mar; 13(3):e071304. PubMed ID: 36882246
[TBL] [Abstract] [Full Text] [Related]
6. Replication competent retrovirus testing (RCR) in the National Gene Vector Biorepository: No evidence of RCR in 1,595 post-treatment peripheral blood samples obtained from 60 clinical trials.
Cornetta K; Yao J; House K; Duffy L; Adusumilli PS; Beyer R; Booth C; Brenner M; Curran K; Grilley B; Heslop H; Hinrichs CS; Kaplan RN; Kiem HP; Kochenderfer J; Kohn DB; Mailankody S; Norberg SM; O'Cearbhaill RE; Pappas J; Park J; Ramos C; Ribas A; Rivière I; Rosenberg SA; Sauter C; Shah NN; Slovin SF; Thrasher A; Williams DA; Lin TY
Mol Ther; 2023 Mar; 31(3):801-809. PubMed ID: 36518078
[TBL] [Abstract] [Full Text] [Related]
7. The 17-Gene Genomic prostate Score Test Is Prognostic for Outcomes After Primary External Beam Radiation Therapy in Men With Clinically Localized prostate cancer.
Janes JL; Boyer MJ; Bennett JP; Thomas VM; De Hoedt AM; Edwards V DK; Singla PK; Abran JM; Aboushwareb T; Salama JK; Freedland SJ
Int J Radiat Oncol Biol Phys; 2023 Jan; 115(1):120-131. PubMed ID: 36306979
[TBL] [Abstract] [Full Text] [Related]
8. Enhanced anti-cancer effects of oestrogen and progesterone co-therapy against colorectal cancer in males.
Mahbub AA; Aslam A; Elzubier ME; El-Boshy M; Abdelghany AH; Ahmad J; Idris S; Almaimani R; Alsaegh A; El-Readi MZ; Baghdadi MA; Refaat B
Front Endocrinol (Lausanne); 2022; 13():941834. PubMed ID: 36263327
[TBL] [Abstract] [Full Text] [Related]
9. Tumor suppressor role of RBM22 in prostate cancer acting as a dual-factor regulating alternative splicing and transcription of key oncogenic genes.
Jiménez-Vacas JM; Montero-Hidalgo AJ; Gómez-Gómez E; Sáez-Martínez P; Fuentes-Fayos AC; Closa A; González-Serrano T; Martínez-López A; Sánchez-Sánchez R; López-Casas PP; Sarmento-Cabral A; Olmos D; Eyras E; Castaño JP; Gahete MD; Luque RM
Transl Res; 2023 Mar; 253():68-79. PubMed ID: 36089245
[TBL] [Abstract] [Full Text] [Related]
10. cancer incidence and mortality in Australia from 2020 to 2044 and an exploratory analysis of the potential effect of treatment delays during the COVID-19 pandemic: a statistical modelling study.
Luo Q; O'Connell DL; Yu XQ; Kahn C; Caruana M; Pesola F; Sasieni P; Grogan PB; Aranda S; Cabasag CJ; Soerjomataram I; Steinberg J; Canfell K
Lancet Public Health; 2022 Jun; 7(6):e537-e548. PubMed ID: 35660215
[TBL] [Abstract] [Full Text] [Related]
11. Targeting cyclin-dependent kinase 7-association between CDK7 and pMED1 expression in prostate cancer tissue.
Paulsen FO; Kang D; Becker F; Roth D; Joerg V; Dreyer E; Roesch MC; Seidel C; Merseburger AS; Kirfel J; Sailer V; Offermann A; Perner S
Carcinogenesis; 2022 Sep; 43(8):779-786. PubMed ID: 35512686
[TBL] [Abstract] [Full Text] [Related]
12. [A Case of Pelvic Lymph Node Recurrence Detected by PSMA PET/CT after Primary Proton Beam Radiotherapy for prostate cancer].
Ito T; Yamaguchi Y; Fujimoto N; Watabe T; Ishizuya Y; Uemura M; Nonomura N
Hinyokika Kiyo; 2021 Dec; 67(12):543-546. PubMed ID: 34991296
[TBL] [Abstract] [Full Text] [Related]
13. Lysine Demethylase 6B Regulates prostate cancer Cell Proliferation by Controlling c-MYC Expression.
Yıldırım-Buharalıoğlu G
Mol Pharmacol; 2022 Feb; 101(2):106-119. PubMed ID: 34862309
[TBL] [Abstract] [Full Text] [Related]
14. Panobinostat reverses HepaCAM gene expression and suppresses proliferation by increasing histone acetylation in prostate cancer.
Chen E; Liu N; Zhao Y; Tang M; Ou L; Wu X; Luo C
Gene; 2022 Jan; 808():145977. PubMed ID: 34592353
[TBL] [Abstract] [Full Text] [Related]
15. Genetic and epigenetic bases of prostate tumor cell radioresistance.
Kutilin D
Klin Onkol; 2021; 34(3):220-234. PubMed ID: 34362257
[TBL] [Abstract] [Full Text] [Related]
16. Genetic and epigenetic bases of prostate tumor cell radioresistance.
Kutilin Denis
Ceska Gynekol; 2021; 86(3):220-234. PubMed ID: 34192880
[TBL] [Abstract] [Full Text] [Related]
17. ZRSR2 overexpression is a frequent and early event in castration-resistant prostate cancer development.
He H; Hao J; Dong X; Wang Y; Xue H; Qu S; Choi SYC; Ci X; Wang Y; Wu R; Shi M; Zhao X; Collins C; Lin D; Wang Y
Prostate Cancer Prostatic Dis; 2021 Sep; 24(3):775-785. PubMed ID: 33568749
[TBL] [Abstract] [Full Text] [Related]
18. Blood-based gene expression signature associated with metastatic castrate-resistant prostate cancer patient response to abiraterone plus prednisone or enzalutamide.
Haas NB; LaRiviere MJ; Buckingham TH; Cherkas Y; Calara-Nielsen K; Foulk B; Patel J; Gross S; Smirnov D; Vaughn DJ; Amaravadi R; Wellen KE; Savitch SL; Majmundar KJ; Black TA; Yee SS; He M; Min EJ; Long Q; Jones JO; Pal SK; Carpenter EL
Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):448-456. PubMed ID: 33009489
[TBL] [Abstract] [Full Text] [Related]
19. Survival of Contemporary Patients With Non-metastatic Small-cell Carcinoma of Urinary Bladder, According to Alternative treatment Modalities.
Luzzago S; Palumbo C; Rosiello G; Knipper S; Pecoraro A; Nazzani S; Tian Z; Musi G; Montanari E; Shariat SF; Saad F; Briganti A; de Cobelli O; Karakiewicz PI
Clin Genitourin Cancer; 2020 Aug; 18(4):e450-e456. PubMed ID: 32146153
[TBL] [Abstract] [Full Text] [Related]
20. BAP18 is involved in upregulation of ccnd1/2 transcription to promote cell growth in oral squamous cell carcinoma.
Wang X; Wang C; Yan G; Kang Y; Sun G; Wang S; Zou R; Sun H; Zeng K; Song H; Liu W; Sun N; Liu W; Zhao Y
EBioMedicine; 2020 Mar; 53():102685. PubMed ID: 32113162
[TBL] [Abstract] [Full Text] [Related]
[Next]
